Facet Hypertrophy | Diagnosis & Disease Information
Etiology and Risk Factors. Spondylosis, or degeneration of the spine, is the most common cause of facet joint disease. Osteoarthritis, or degeneration that is due to natural wear and tear, is a process that involves cytokines and proteolytic enzymes. Other causes of facet hypertrophy can include trauma caused by car accidents, sports injuries, or falls. 1
2022 ACR/AAHKS Guidelines for Management of
Apr 6, 2022 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty: guideline summary.
Hydroxyapatite Crystal Deposition Disease (HADD)
Nov 15, 2022 · History and Epidemiology. A typically uniarticular condition, hydroxyapatite (HA) crystal deposition disease (HADD) is marked by the presence of hydroxyapatite crystals in the periarticular soft tissues, especially the tendons 1.HA is a mineral found in normal bone, but when it builds up in and around the joints it can cause inflammation, tenderness, and pain.
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
Aug 9, 2022 · Undifferentiated connective tissue disease (UCTD) is a diagnosis of exclusion. Patients who present with clinical and serolotical manifestations that suggest a systemic autoimmune disease but do not fulfill criteria for defined connective tissue disease (eg, systemic lupus erythematosus, scleroderma, myositis, rheumatoid arthritis, Sjogren's syndrome) are classified to have UCTD.
Calcium Pyrophosphate Deposition Disease (CPPD)
Oct 5, 2022 · History and Epidemiology. Calcium pyrophosphate deposition disease (CPPD) is a crystal deposition arthropathy that involves the synovial and periarticular tissues, 1 often characterized by painful swelling in one or more joints. 2 Other names that have been traditionally used for CPPD are chondrocalcinosis, pyrophosphate arthropathy, and most especially, pseudogout. 3 It is commonly known as ...
Leukocytoclastic Vasculitis - Rheumatology Advisor
Aug 4, 2022 · Diagnostic Workup. The diagnostic workup for leukocytoclastic vasculitis does not follow a uniform series of steps. If the skin biopsy indicates a diagnosis of leukocytoclastic vasculitis, the goal is to determine whether there is systemic involvement and …
ACR Releases 2024 Guideline Summary for Lupus Nephritis
Nov 25, 2024 · Recommended treatment includes pulse intravenous glucocorticoids (250-1000 mg/day for 1-3 days) transitioning to oral dosing (≤0.5 mg/kg/day), with the goal of tapering to a dose of 5 mg/day or less by 6 months.
FDA Roundup: Rheumatology Drug Alerts 2024
Mar 5, 2024 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.
PATIENT FACT SHEET Copyright © 2024 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form ...
Ehlers-Danlos Syndrome - Rheumatology Advisor
Aug 10, 2022 · Ehlers-Danlos syndrome is a group of inherited connective tissue disorders that primarily affects the skin, joints, and blood vessel walls1 but can affect every organ system and result in significant morbidity and mortality. Typical clinical manifestations are skin hyperelasticity, hypermobility of joints, the fragility of blood vessels, and …